Immune response to SARS-CoV-2 vaccines in patients with multiple sclerosis in Argentina: prospective and multicenter study

被引：0

作者：

Vazquez, G. ^{[1
,2
]}

Lamas, P. ^{[3
]}

Remolins, C. ^{[3
]}

Appiani, F. ^{[4
]}

Martinez, A. ^{[5
]}

Curbelo, M. C. ^{[5
]}

Pirola, D. ^{[6
]}

Natalia, B. ^{[7
]}

Chuluyan, E. ^{[3
]}

Carra, A. ^{[4
,5
]}

机构：

[1] Favaloro Fdn Hosp, Buenos Aires, DF, Argentina

[2] INECO, Buenos Aires, DF, Argentina

[3] Univ Buenos Aires, Fac Med, CONICET, CEFYBO, Buenos Aires, DF, Argentina

[4] Favaloro Fdn Hosp, Neurosci, Buenos Aires, DF, Argentina

[5] Britann Hosp, Demyelinating Serv, Buenos Aires, DF, Argentina

[6] Favaloro Fdn Hosp, Cent Lab, Buenos Aires, DF, Argentina

[7] GADOR SA, Med & Sci Dept, Buenos Aires, DF, Argentina

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EP1113

引用

页码：879 / 879

页数：1

共 50 条

[41] Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies
M. Allman
E. Tallantyre
N. P. Robertson
Journal of Neurology, 2022, 269 : 2259 - 2261
[42] B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study
Conte, William L.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
[43] SARS-CoV-2 Vaccination in Patients with Pauci-Immune Glomerulonephritis: A Multicenter Study
Sardeli, Angeliki
Dounousi, Evangelia
Gkalitsiou, Dimitra
Kantartzi, Konstantia
Pelagia, Kriki
Liakopoulos, Vassilios
Marinaki, Smaragdi
Panagiotis, Giannakopoulos
Moustakas, Georgios
Lionaki, Sophia
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
[44] COVID-19 antibody response after two doses of SARS-CoV-2 vaccines in multiple sclerosis patients; an update to the previous study
Ozakbas, S.
Baba, C.
Ozcelik, S.
Ozdogar, A. T.
Kaya, E.
Dogan, Y.
Cevik, S.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 764 - 765
[45] SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments
Canedo-Marroquin, Gisela
Saavedra, Farides
Andrade, Catalina A.
Berrios, Roslye, V
Rodriguez-Guilarte, Linmar
Opazo, Maria C.
Riedel, Claudia A.
Kalergis, Alexis M.
FRONTIERS IN IMMUNOLOGY, 2020, 11
[46] Is SARS-CoV-2 important for multiple sclerosis?
Chyzhyk, V.
Sialitski, M.
Boika, A.
Bahamaz, V.
Mazurenka, K.
Ponomarev, V.
EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 492 - 492
[47] Multiple sclerosis treatment blunts SARS-CoV-2 antibody response
Lemprière S.
Nature Reviews Neurology, 2021, 17 (9) : 525 - 525
[48] Assessing the immune response to SARS-CoV-2 mRNA vaccines in patients with secondary progressive multiple sclerosis treated with siponimod (AMA-VACC clinical trial)
Ziemssen, T.
Rauser, B.
Ettle, B.
Groth, M.
Bopp, T.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 668 - 668
[49] SARS-CoV-2 in semen: a multicenter prospective study and literature review
Cochetti, Giovanni
Del Zingaro, Michele
Maiolino, Giuseppe
Paladini, Alessio
Mearini, Matteo
Schiavina, Riccardo
Bianchi, Lorenzo
De Angelis, Lorenzo
Panciarola, Mattia
Camilloni, Barbara
Brunocilla, Eugenio
Mearini, Ettore
BASIC AND CLINICAL ANDROLOGY, 2024, 34 (01)
[50] Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
Raeuber, Saskia
Korsen, Melanie
Huntemann, Niklas
Rolfes, Leoni
Muentefering, Thomas
Dobelmann, Vera
Hermann, Alexander M.
Koelsche, Tristan
Lipinski, Karin von Wnuck
Schroeter, Christina B.
Nelke, Christopher
Regner-Nelke, Liesa
Ingwersen, Jens
Pawlitzki, Marc
Teegen, Bianca
Barnett, Michael Harry
Hartung, Hans-Peter
Aktas, Orhan
Albrecht, Philipp
Levkau, Bodo
Melzer, Nico
Ruck, Tobias
Meuth, Sven G.
Kremer, David
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09): : 978 - 985

← 1 2 3 4 5 →